You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTocilizumab
Accession NumberDB06273
TypeBiotech
GroupsApproved
Description

Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010.

Protein structureDb06273
Related Articles
Protein chemical formulaC6428H9976N1720O2018S42
Protein average weight148000.0 Da
SequencesNot Available
Synonyms
Atlizumab
MRA
RoActemra®
External Identifiers
  • R-1569
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Actemrasolution162 mgsubcutaneousHoffmann La Roche Limited2014-05-30Not applicableCanada
Actemrasolution400 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrasolution200 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrasolution80 mgintravenousHoffmann La Roche Limited2010-05-26Not applicableCanada
Actemrainjection, solution180 mg/mLsubcutaneousGenentech, Inc.2013-10-21Not applicableUs
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Actemrainjection, solution, concentrate20 mg/mLintravenousGenentech, Inc.2010-01-08Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII031V2H011
CAS number375823-41-9
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
PharmacodynamicsA decrease in C-reactive protein (CRP) was noted as early as week 2. Changes in pharmacodynamic parameters were observed (i.e., decreases in rheumatoid factor, erythrocyte sedimentation rate (ESR), serum amyloid A and increases in hemoglobin) with both doses, however the greatest improvements were observed with 8 mg per kg tocilizumab. Similar pharmacodynamic changes were also observed in active polyarticular juvenile idiopathic arthritis and active systemic juvenile idiopathic arthritis patients.
Mechanism of actionInterleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Deregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn's disease (CD) and systemic lupus erythematosus (SLE). Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.
Related Articles
AbsorptionWhen 4 mg/kg of tocilizumab was given every 4 weeks to RA patients, the pharmacokinetic parameters at steady state are as follows: AUC = 13000 ± 5800 mcg∙h/mL; Cmax = 88.3 ± 41.4 mcg/mL. Tocilizumab accumulates following repeated doses. Furthermore, an increased body weight may increase plasma levels of tocilizumab. When a dose of 8 mg/kg of tocilizumab is given to PJIA patients, the pharmacokinetic parameters are as follows: AUC = 29500 ± 8660 mcg∙h/mL; Cmax = 182 ± 37 mcg/mL. When a dose of 8 mg/kg of tocilizumab is given to SJIA patients, the pharmacokinetic parameters are as follows: AUC = 32200 ± 9960 mcg∙h/mL; Cmax = 245 ± 57.2 mcg/mL.
Volume of distribution

In rheumatoid arthritis patients the central volume of distribution was 3.5 L and the peripheral volume of distribution was 2.9 L, resulting in a volume of distribution at steady state of 6.4 L.

In pediatric patients with PJIA, the central volume of distribution was 1.98 L, the peripheral volume of distribution was 2.1 L, resulting in a volume of distribution at steady state of 4.08 L.

In pediatric patients with SJIA, the central volume of distribution was 0.94 L, the peripheral volume of distribution was 1.60 L resulting in a volume of distribution at steady state of 2.54 L.

Protein bindingNot Available
MetabolismNot Available
Route of eliminationFollowing intravenous dosing, tocilizumab undergoes biphasic elimination from the circulation.
Half lifeThe half-life of tocilizumab is concentration-dependent. The concentration-dependent apparent half-life is up to 11 days for 4 mg/kg and up to 13 days for 8 mg/kg every 4 weeks in patients with RA at steady-state. The half-life in children with PJIA is up to 16 days. The half-life in pediatric patients with SJIA is up to 23 days.
Clearance

The clearance of tocilizumab decreases with increasing dose. At the 10 mg/kg single dose in RA patients, mean clearance was 0.29 ± 0.10 mL/hr/kg. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear clearance and the nonlinear clearance. At low concentrations, concentration-dependent nonlinear clearance is dominant. At high concentrations, linear clearance dominates. The estimated linear clearances for specific patient populations are as follows:
RA = 12.5 mL/h;
PJIA, pediatric patients = 5.8 mL/h;
SJIA, pediatric patients = 7.1 mL/h.

ToxicityMost common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, solutionsubcutaneous180 mg/mL
Injection, solution, concentrateintravenous20 mg/mL
Solutionintravenous200 mg
Solutionintravenous400 mg
Solutionintravenous80 mg
Solutionsubcutaneous162 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341152 No2000-12-122017-12-12Canada
CA2201781 No2010-01-122015-06-07Canada
Properties
StateLiquid
Experimental PropertiesNot Available
References
Synthesis ReferenceNot Available
General References
  1. Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther. 2005 May;5(5):683-90. [PubMed:15934843 ]
External Links
ATC CodesL04AC07
AHFS Codes
  • 92:36
PDB EntriesNot Available
FDA labelDownload (623 KB)
MSDSDownload (482 KB)
Interactions
Drug Interactions
Drug
AbataceptThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Abatacept.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Tocilizumab.
AdalimumabTocilizumab may increase the immunosuppressive activities of Adalimumab.
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Tocilizumab.
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Tocilizumab.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab.
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Tocilizumab.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Tocilizumab.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Tocilizumab.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Tocilizumab.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.
ArmodafinilThe serum concentration of Armodafinil can be decreased when it is combined with Tocilizumab.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Tocilizumab.
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Tocilizumab.
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Tocilizumab.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Tocilizumab.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Tocilizumab.
BelimumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Belimumab.
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Tocilizumab.
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Tocilizumab.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Tocilizumab.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Tocilizumab.
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Tocilizumab.
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Tocilizumab.
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Tocilizumab.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Tocilizumab.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Tocilizumab.
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Tocilizumab.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Tocilizumab.
Certolizumab pegolTocilizumab may increase the immunosuppressive activities of Certolizumab pegol.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Tocilizumab.
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Tocilizumab.
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Tocilizumab.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Tocilizumab.
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Tocilizumab.
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Tocilizumab.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Tocilizumab.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Tocilizumab.
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Tocilizumab.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Tocilizumab.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Tocilizumab.
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Tocilizumab.
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Tocilizumab.
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Tocilizumab.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Tocilizumab.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tocilizumab.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Tocilizumab.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Tocilizumab.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Tocilizumab.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Tocilizumab.
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Tocilizumab.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Tocilizumab.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Tocilizumab.
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Tocilizumab.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Tocilizumab.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Tocilizumab.
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Tocilizumab.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Tocilizumab.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Tocilizumab.
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Tocilizumab.
Estrone sulfateThe serum concentration of Estropipate can be decreased when it is combined with Tocilizumab.
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Tocilizumab.
EtanerceptTocilizumab may increase the immunosuppressive activities of Etanercept.
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Tocilizumab.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Tocilizumab.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Tocilizumab.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Tocilizumab.
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Tocilizumab.
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Tocilizumab.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Tocilizumab.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Tocilizumab.
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Tocilizumab.
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Tocilizumab.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Tocilizumab.
FosaprepitantThe serum concentration of Fosaprepitant can be decreased when it is combined with Tocilizumab.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Tocilizumab.
golimumabTocilizumab may increase the immunosuppressive activities of golimumab.
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Tocilizumab.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Tocilizumab.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Tocilizumab.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Tocilizumab.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Tocilizumab.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Tocilizumab.
InfliximabTocilizumab may increase the immunosuppressive activities of Infliximab.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Tocilizumab.
IsosorbideThe serum concentration of Isosorbide can be decreased when it is combined with Tocilizumab.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Tocilizumab.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Tocilizumab.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Tocilizumab.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Tocilizumab.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Tocilizumab.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Tocilizumab.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Tocilizumab.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Tocilizumab.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Tocilizumab.
LeflunomideThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Leflunomide.
LenalidomideTocilizumab may increase the immunosuppressive activities of Lenalidomide.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Tocilizumab.
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Tocilizumab.
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Tocilizumab.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Tocilizumab.
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Tocilizumab.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.
MacitentanThe serum concentration of MACITENTAN can be decreased when it is combined with Tocilizumab.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Tocilizumab.
Medroxyprogesterone AcetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Tocilizumab.
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Tocilizumab.
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Tocilizumab.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Tocilizumab.
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Tocilizumab.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Tocilizumab.
NatalizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Tocilizumab.
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Tocilizumab.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Tocilizumab.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Tocilizumab.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Tocilizumab.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Tocilizumab.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.
NorethisteroneThe serum concentration of Norethindrone can be decreased when it is combined with Tocilizumab.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Tocilizumab.
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Tocilizumab.
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Tocilizumab.
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Tocilizumab.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Tocilizumab.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Tocilizumab.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Tocilizumab.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tocilizumab.
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Tocilizumab.
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Tocilizumab.
PomalidomideTocilizumab may increase the immunosuppressive activities of Pomalidomide.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Tocilizumab.
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Tocilizumab.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Tocilizumab.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Tocilizumab.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Tocilizumab.
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Tocilizumab.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Tocilizumab.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Tocilizumab.
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Tocilizumab.
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Tocilizumab.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Tocilizumab.
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Tocilizumab.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Tocilizumab.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Tocilizumab.
RoflumilastRoflumilast may increase the immunosuppressive activities of Tocilizumab.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Tocilizumab.
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Tocilizumab.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Tocilizumab.
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Tocilizumab.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Tocilizumab.
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Tocilizumab.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Tocilizumab.
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Tocilizumab.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Tocilizumab.
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Tocilizumab.
StiripentolThe serum concentration of Stiripentol can be decreased when it is combined with Tocilizumab.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Tocilizumab.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Tocilizumab.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Tocilizumab.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Tocilizumab.
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Tocilizumab.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Tocilizumab.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Tocilizumab.
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Tocilizumab.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Tocilizumab.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Tocilizumab.
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.
ThalidomideTocilizumab may increase the immunosuppressive activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Tocilizumab.
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Tocilizumab.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Tocilizumab.
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Tocilizumab.
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Tocilizumab.
TofacitinibThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Tofacitinib.
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Tocilizumab.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Tocilizumab.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Tocilizumab.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Tocilizumab.
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Tocilizumab.
TrastuzumabTrastuzumab may increase the neutropenic activities of Tocilizumab.
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Tocilizumab.
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Tocilizumab.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Tocilizumab.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Tocilizumab.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Tocilizumab.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Tocilizumab.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Tocilizumab.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Tocilizumab.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Tocilizumab.
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Tocilizumab.
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Tocilizumab.
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Tocilizumab.
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Tocilizumab.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antibody
General Function:
Protein homodimerization activity
Specific Function:
Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.
Gene Name:
IL6R
Uniprot ID:
P08887
Molecular Weight:
51547.015 Da
References
  1. Smolen JS, Maini RN: Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5. Epub 2006 Jul 28. [PubMed:16899109 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:20 / Updated on March 14, 2016 10:03